کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2116423 1084908 2010 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
چکیده انگلیسی

Glioblastoma (GBM) is an extremely aggressive, infiltrative tumor with a poor prognosis. The regulatory approval of bevacizumab for recurrent GBM has confirmed that molecularly targeted agents have potential for GBM treatment. Preclinical data showing that SRC and SRC-family kinases (SFKs) mediate intracellular signaling pathways controlling key biologic/oncogenic processes provide a strong rationale for investigating SRC/SFK inhibitors, e.g., dasatinib, in GBM and clinical studies are underway. The activity of these agents against solid tumors suggests that they may also be useful in treating brain metastases. This article reviews the potential for using SRC/SFK inhibitors to treat GBM and brain metastases.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Letters - Volume 298, Issue 2, 8 December 2010, Pages 139–149
نویسندگان
, , , ,